Does Bactrim Cover Staphylococcus epidermidis?
Yes, Bactrim (trimethoprim-sulfamethoxazole) does provide coverage against Staphylococcus epidermidis, though with important caveats regarding resistance patterns and clinical efficacy.
Microbiological Activity
Bactrim demonstrates in vitro activity against S. epidermidis, but the susceptibility is notably lower compared to S. aureus. Research shows that approximately 81% of S. epidermidis isolates were susceptible to trimethoprim-sulfamethoxazole in laboratory testing 1. However, this susceptibility varies significantly based on clinical context—about 30% of clinically significant S. epidermidis strains showed resistance, while only 12.6% of normal flora strains were resistant 2.
The MIC90 (minimum inhibitory concentration for 90% of isolates) for S. epidermidis is between 2-4 mg/l, which is notably higher than for S. aureus 3. This suggests that while Bactrim has activity, S. epidermidis is inherently less susceptible than other staphylococcal species 4.
Clinical Guideline Support
Major infectious disease guidelines include trimethoprim-sulfamethoxazole as an acceptable option for staphylococcal skin and soft tissue infections, which would encompass S. epidermidis when it is the causative pathogen 5, 6, 7. The IDSA guidelines specifically list TMP-SMX for both MSSA and MRSA skin infections 6, 7, and since S. epidermidis shares similar resistance mechanisms with S. aureus, this coverage extends to coagulase-negative staphylococci.
For outpatient treatment of purulent skin infections where staphylococci are suspected, oral TMP-SMX is recommended at 1-2 double-strength tablets twice daily for adults 5, 8.
Critical Limitations
Resistance Concerns
- Approximately 30% of clinically significant S. epidermidis strains demonstrate resistance to trimethoprim 2
- Resistance rates have remained relatively stable but vary by institution and geographic location
- The synergistic effect of trimethoprim-sulfamethoxazole is less pronounced against S. epidermidis compared to S. aureus 4
Thymidine Interference
A unique challenge with S. epidermidis is that minimal amounts of thymidine in tissues can antagonize the bactericidal activity of TMP-SMX 1, 9. This means that in vitro susceptibility may not correlate with in vivo bactericidal activity, particularly in tissue-rich environments where thymidine is present.
Clinical Context Matters
For device-related infections (where S. epidermidis is particularly common), source control through device removal is often more critical than antibiotic choice alone. Bactrim may have limited efficacy in biofilm-associated infections typical of S. epidermidis on prosthetic materials.
Practical Recommendations
Use Bactrim for S. epidermidis infections when:
- Susceptibility testing confirms sensitivity
- The infection is in soft tissue without significant biofilm formation
- No prosthetic material is involved, or device removal is planned
- Local resistance patterns support its use (<20% resistance)
Avoid or use alternative agents when:
- Prosthetic device infection without planned removal
- Known high local resistance rates (>30%)
- Severe or deep-seated infections requiring guaranteed bactericidal activity
- Bloodstream infections where vancomycin or daptomycin would be preferred
For empiric therapy of suspected S. epidermidis infections, consider that vancomycin remains the gold standard for serious infections, particularly those involving prosthetic materials or bloodstream 5, 7. Bactrim can be considered for step-down therapy after susceptibility confirmation or for less severe soft tissue infections.
The FDA-approved indications for Bactrim include urinary tract infections caused by susceptible organisms but do not specifically list S. epidermidis by name 10. However, the drug's mechanism of action (inhibiting sequential steps in folate synthesis) is effective against susceptible staphylococcal species 10.